Evaluating only Neon Therapeutics’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Acquisition gone wrong.
Key Events Timeline
FOUNDING
FUNDING
ACQUISITION ATTEMPT
SHUTDOWN
Full Analysis
Free · no account needed
Documented cause
Neon Therapeutics raised $88M to develop personalized neoantigen vaccines for cancer. The company pioneered individualized tumor mutation profiling for immunotherapy. In 2020, BioNTech acquired Neon in a $67M deal primarily to gain access to the team's neoantigen expertise for its mRNA cancer vaccine programs. Neon's existing clinical programs were discontinued and the brand ceased to exist.
Lesson
“Personalized cancer vaccine platforms must validate at scale faster than competing approaches — once mRNA proved faster and cheaper, the older platforms became acquisition targets at below-raise valuations.”